Skip to main content

Development of novel treatment strategies based on knowledge of cellular dysfunction in diabetes

Objective

A reduction in functional pancreatic beta cell mass is the key feature of type 1 and type 2 diabetes. Beta cell failure is exacerbated in the context of obesity and insulin resistance. Brown adipose tissue (BAT) is a highly metabolic organ, mediating energy dissipation and glucose disposal, thus contributing to maintain energy balance. BAT dysfunction contributes to obesity and impaired glucose metabolism, increasing functional demand on the beta cells. The cellular dysfunction of beta cells and BAT in diabetes is the fruit of defective signal transduction and organelle function, and the vulnerability to these molecular defects may be modulated by diabetes genes. To identify the crosstalk and pathways responsible for beta cell and BAT dysfunction and beta cell apoptosis in diabetes at its real level of complexity, this consortium will use cutting edge genetics, functional (epi)genomics, molecular biology and computational tools to reach an accurate organelle and cell diagnosis. This diagnosis will be used to define novel targets for intervention to prevent dysfunction and facilitate recovery of functionally impaired metabolic tissues. Some of these targets have already been identified by consortium members, including endoplasmic reticulum (ER) stress and mitochondrial dysfunction and apoptosis. Since many of these targets are related to dysfunction of specific organelles, we will focus on the novel concept of organelle therapy, aiming to preserve mitochondrial and ER function by the use of viral vectors and small molecule chemical probes. We will thus follow a two-pronged approach, namely a focused approach to restore known and specific cellular/organelle dysfunctions and a systems biology approach to identify novel targets for intervention. This, in combination with high throughput screening of large compound libraries, will translate discoveries into innovative therapeutic strategies that halt destruction and facilitate recovery of cell dysfunction in diabetes.

Field of science

  • /natural sciences/biological sciences/molecular biology
  • /medical and health sciences/clinical medicine/endocrinology/diabetes

Call for proposal

FP7-HEALTH-2011-two-stage
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

UNIVERSITE LIBRE DE BRUXELLES
Address
Avenue Franklin Roosevelt 50
1050 Bruxelles
Belgium
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 354 000
Administrative Contact
Angelique Greindl (Ms.)

Participants (10)

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 994 000
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Renata Schaeffer (Ms.)
UNIVERSITE DE LAUSANNE
Switzerland
EU contribution
€ 497 000
Address
Quartier Unil-centre Bâtiment Unicentre
1015 Lausanne
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Nicole Vouilloz (Ms.)
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
United States
EU contribution
€ 450 000
Address
North Torrey Pines Road 10901
92037 1005 La Jolla Ca
Activity type
Research Organisations
Administrative Contact
Kathlyn L. Huson (Ms.)
UNIVERSITAT DE BARCELONA
Spain
EU contribution
€ 474 000
Address
Gran Via De Les Corts Catalanes 585
08007 Barcelona
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Xavier Gutiérrez (Mr.)
MAX IV Laboratory, Lund University
Sweden
EU contribution
€ 485 000
Address
Paradisgatan 5C
22100 Lund
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Jacqueline Postma (Dr.)
TEKNOLOGIAN TUTKIMUSKESKUS VTT

Participation ended

Finland
EU contribution
€ 286 333,60
Address
Tekniikantie 4 A
02044 VTT Espoo
Activity type
Research Organisations
Administrative Contact
Sinikka Soirinsuo (Ms.)
MEDIZINISCHE HOCHSCHULE HANNOVER
Germany
EU contribution
€ 482 000
Address
Carl-neuberg-strasse 1
30625 Hannover
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Angela Steinhusen (Ms.)
DNA VISION SA
Belgium
EU contribution
€ 356 000
Address
Avenue G Lemaitre 25
6041 Gosselies
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Dimitri Lhoste (Mr.)
SIRION BIOTECH GMBH
Germany
EU contribution
€ 411 000
Address
Am Klopferspitz 19
82152 Planegg Martinsried
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Christian Thirion (Dr.)
NOVO NORDISK INVEST 4 A/S
Denmark
EU contribution
€ 209 666,40
Address
Novo Alle 1
2880 Bagsvaerd
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Allan Arp (Mr.)